Background information
- Mpox (monkeypox) virus overview: includes information on transmission and clinical signs / symptoms as well as links to important documents and resources (Ontario Ministry of Health)
- Mpox fact sheet: provides an overview of the virus, transmission, epidemiology, clinical considerations including treatment and prevention (World Health Organization)
Mpox can have range of clinical presentations. Common symptoms include fever; new rash or lesions in the mouth, genital, and/or peri-anal region; rectal pain; and lymphadenopathy. Symptoms of mpox in vaccinated individuals may be milder or subclinical; in at-risk groups, such as those with new and/or multiple partners, use a lower threshold to test. Although most cases in Ontario have been identified among men who have sex with men, anyone can acquire mpox infection.
| Laboratory testing |
Who to test for mpox
Collecting specimens for mpox testing
Testing for other pathogens
Sending specimens to the Public Health Ontario Lab (PHOL)
|
| Infection Prevention and Control |
Are there additional IPAC requirements for mpox testing?
Management of Patients Tested for Mpox Any patient you suspect has mpox (including anyone you test for mpox) should be advised of mitigation measures to reduce transmission. Individuals do not need to self-isolate but should adhere to risk mitigation measures (see below) if all of the following criteria are met:
Individuals unable to adhere to risk mitigation measures should self-isolate. If symptoms progress or the individual is no longer able to adhere to risk mitigation measures such that the above criteria are no longer met, the individual should self-isolate. If it is not feasible to assess whether someone with suspected or confirmed mpox infection should be self-isolating, please consider recommending self-isolation until further assessed by OPH. Please flag this when reporting to OPH so that OPH can contact and assess the individual in a timely manner. Risk mitigation measures include:
For more information, refer to Recommendations for the management of cases and contacts of mpox in Ontario. |
| Reporting to Public Health |
|
Mpox is reportable immediately to Ottawa Public Health (this includes those tested for whom lab results are not yet available):
|
| Vaccination |
|
The Imvamune® live non-replicating vaccine for mpox is available to select eligible persons for both Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP). Please direct eligible persons interested in accessing this vaccine to our general mpox virus page for more information. |
| Physician Resources |
|
|
Patient resources |
|
Contact us
Monday to Friday from 8:30 am to 4:30 pm: Call 613-580-2424, extension 24224, select your language of choice by pressing 1 or 2 and then and leave a detailed, confidential message including your contact information.
After hours, on weekends, or holidays: Call 3-1-1 and ask to speak to Public Health on call. To have your call prioritized as a health care provider, please identify yourself and your reason for calling; your call will be prioritized for answer by the next available public health nurse.
Contact Us
